New approach of treatment of hepatitis C virus genotype 4

Chronic hepatitis C virus infection is one of the most important health problems. Optimal therapy for patients with hepatitis C virus genotype 4 infection is changing rapidly; the standard of care for a long time has been a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV) with modest response rates and considerable adverse events. Sofosbuvir is a direct-acting pyrimidine nucleotide analog; the first NS5B HCV polymerase inhibitor. It has a potent activity against all HCV genotypes. The innate immune system represents the initial line of host defense mechanism against invading pathogen. The treatment modalities either with Sofosbuvir plus ribavirin or Sofosbuvir plus ribavirin and pegylated Interferon is highly effective in patients infected with HCV genotype 4.